Core Viewpoint - Analysts expect Edwards Lifesciences to report quarterly earnings of $0.60 per share, reflecting a year-over-year decline of 9.1%, with revenues projected at $1.4 billion, down 12.2% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions to stock performance, with empirical studies showing a strong correlation between earnings estimate revisions and short-term price performance [2] Key Metrics Overview - Analysts predict 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' will reach $113.82 million, indicating a year-over-year increase of 56.1% [4] - 'Net Sales by Product Group- Surgical Structural Heart' is forecasted to be $254.51 million, reflecting a decrease of 4.4% from the year-ago quarter [4] - 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' is expected to reach $1.03 billion, showing a year-over-year increase of 2.2% [5] - 'Net Sales- Europe' is projected at $357.01 million, indicating a decline of 2.9% from the prior-year quarter [5] - 'Net Sales- Outside of the United States' is estimated at $573.77 million, reflecting a year-over-year decrease of 12.7% [6] - 'Net Sales- United States' is expected to be $849.03 million, down 9.8% from the previous year [6] - 'Net Sales- Japan' is projected to reach $96.40 million, indicating a year-over-year decline of 13% [6] - 'Net Sales- Rest of World' is expected to be $120.36 million, reflecting a significant decrease of 32.7% from the year-ago quarter [7] Stock Performance - Edwards Lifesciences shares have increased by 0.8% over the past month, contrasting with the Zacks S&P 500 composite's decline of 6.9%, with a Zacks Rank of 3 (Hold) indicating expected performance in line with the overall market [7]

Wall Street analysts expect Dow Inc. (DOW) to post quarterly loss of $0.02 per share in its upcoming report, which indicates a year-over-year decline of 103.6%. Revenues are expected to be $10.27 billion, down 4.6% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 46% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a compan ...

Wall Street analysts expect Nasdaq (NDAQ) to post quarterly earnings of $0.77 per share in its upcoming report, which indicates a year-over-year increase of 22.2%. Revenues are expected to be $1.23 billion, up 10.2% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announ ...

Core Viewpoint - Analysts forecast Merck's quarterly earnings to be $2.16 per share, reflecting a year-over-year increase of 4.4%, while revenues are expected to decline by 1.9% to $15.48 billion [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 4%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Projections - Sales for Oncology product Keytruda are projected to reach $7.55 billion, an increase of 8.7% year-over-year [5]. - Hospital Acute Care sales for Zerbaxa are expected to be $63.07 million, reflecting a 12.6% increase from the previous year [5]. - Alliance revenue for Lynparza is estimated at $300.62 million, indicating a 3% increase year-over-year [5]. - Sales for Oncology Alliance revenue Lenvima are projected at $234.33 million, showing an 8.1% decline from the prior year [6]. - U.S. sales for Keytruda are expected to be $4.47 billion, reflecting an 8.6% increase year-over-year [6]. - International sales for Keytruda are projected at $3.08 billion, indicating an 8.8% increase from the previous year [7]. - U.S. sales for Lynparza are expected to reach $121.96 million, reflecting a 9.7% decline year-over-year [7]. - International sales for Lynparza are projected at $178.66 million, indicating a 13.8% increase from the prior year [8]. - U.S. sales for Lenvima are expected to be $155.59 million, reflecting a 10.1% decline year-over-year [8]. - International sales for Lenvima are projected at $78.74 million, indicating a 4% decline from the previous year [9]. - U.S. sales for Zerbaxa are expected to reach $36.81 million, reflecting an 11.5% increase year-over-year [9]. - International sales for Zerbaxa are projected at $26.26 million, indicating a 14.2% increase from the prior year [10]. Stock Performance - Merck's shares have decreased by 17.7% over the past month, compared to a 6.9% decline in the Zacks S&P 500 composite [10].

Core Viewpoint - The upcoming earnings report from Ameriprise Financial Services (AMP) is anticipated to show an increase in quarterly earnings and revenues compared to the previous year, with earnings per share expected to be $9.12, reflecting an 8.7% increase, and revenues projected at $4.39 billion, indicating a 7.1% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate has been revised 3.8% lower over the last 30 days, indicating a reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts expect 'Revenues- Net investment income' to be $845.60 million, a decrease of 6.2% from the previous year [5]. - 'Revenues- Premiums, policy and contract charges' are projected to reach $391.68 million, showing a slight increase of 0.4% year-over-year [5]. - 'Revenues- Distribution fees' are estimated at $534.87 million, reflecting a 5.7% increase compared to the year-ago quarter [5]. - 'Revenues- Other revenues' are forecasted to be $132.12 million, indicating a 2.4% increase year-over-year [6]. Assets Under Management - Total Assets Under Management (AUM) is expected to reach $1.18 billion, up from $1.13 billion in the same quarter last year [6]. - Total Assets Under Administration are projected at $317.49 million, compared to $297.46 million in the previous year [7]. - Total Assets Under Management and Administration are estimated to be $1.49 billion, an increase from $1.42 billion year-over-year [7]. - AUM for Asset Management is expected to be $646.27 million, slightly down from $652.08 million in the same quarter last year [8]. - Total Client Assets are projected to reach $1,030.12 billion, up from $953.77 billion year-over-year [9]. Advisor Metrics - The number of total advisors is expected to reach 10,450, compared to 10,364 in the previous year [9]. Stock Performance - Ameriprise shares have decreased by 5.8% over the past month, while the Zacks S&P 500 composite has declined by 6.9% [11].

Company Overview - Masimo Corporation (MASI) is positioned as an intriguing investment choice within the Medical - Instruments sector, supported by solid earnings estimate revisions [1][3]. - The company has experienced a positive shift in earnings estimates, indicating a more bullish outlook from analysts regarding its short and long-term prospects [3]. Industry Context - The Medical - Instruments industry currently holds a Zacks Industry Rank of 66 out of over 250 industries, suggesting a favorable position compared to other sectors [2]. - The industry is experiencing broad trends that are positively impacting securities across the board, indicating a rising tide effect [2]. Earnings Estimates - Over the past month, Masimo's current quarter earnings estimates have increased from $1.17 per share to $1.24 per share, while current year estimates have risen from $5.07 per share to $5.28 per share [4]. - These revisions have contributed to Masimo earning a Zacks Rank 1 (Strong Buy), highlighting the company's strong market position [4]. Investment Consideration - Given the strong performance of the industry and the positive earnings revisions, Masimo is recommended as a compelling option for investors seeking opportunities in a robust industry segment [5].

Wall Street expects a year-over-year increase in earnings on lower revenues when Merck (MRK) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 24. On the othe ...

The upcoming report from Chipotle Mexican Grill (CMG) is expected to reveal quarterly earnings of $0.28 per share, indicating an increase of 3.7% compared to the year-ago period. Analysts forecast revenues of $2.94 billion, representing an increase of 8.7% year over year.Over the last 30 days, there has been a downward revision of 2.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over ...

The upcoming report from Newmont Corporation (NEM) is expected to reveal quarterly earnings of $0.84 per share, indicating an increase of 52.7% compared to the year-ago period. Analysts forecast revenues of $4.54 billion, representing an increase of 13% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 14.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to ...

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.10 per share, reflecting a 0.2% decline year over year, with revenues expected to reach $10.25 billion, down 0.9% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1][2]. - Revisions to earnings estimates are crucial for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2]. Revenue Projections - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.61 billion, indicating a decline of 2.1% from the prior-year quarter [4]. - 'Revenues- Specialty Diagnostics' is expected to be $1.10 billion, reflecting a decrease of 0.5% year over year [4]. - 'Revenues- Life Sciences Solutions' is projected at $2.28 billion, showing a year-over-year change of -0.3% [4]. Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is expected to reach $1.73 billion, suggesting a year-over-year increase of 2.5% [5]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.43 billion, indicating a decline of 1.7% year over year [5]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.88 billion, reflecting a growth of 0.8% [5]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $368.42 million, indicating a year-over-year increase of 6.5% [6]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.60 billion, reflecting a decrease of 0.7% from the year-ago quarter [6]. Stock Performance - Shares of Thermo Fisher have shown a return of -15.7% over the past month, compared to a -6.3% change in the Zacks S&P 500 composite [6].